In today’s session Amgen, Inc. (AMGN) recorded an unusually high (208) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious AMGN decrease. With 208 contracts traded and 7454 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: AMGN161118P00141000 closed last at: $5.5 or 11.1% up. About 3.56 million shares traded hands. Amgen, Inc. (NASDAQ:AMGN) has declined 6.42% since April 8, 2016 and is downtrending. It has underperformed by 12.07% the S&P500.
Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage
Out of 17 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 59% are positive. Amgen Inc. has been the topic of 29 analyst reports since August 3, 2015 according to StockzIntelligence Inc. On Wednesday, June 29 the stock rating was initiated by Bernstein with “Market Perform”. The firm has “Hold” rating given on Friday, August 26 by Gabelli. Vetr upgraded the shares of AMGN in a report on Friday, August 21 to “Buy” rating. The firm has “Outperform” rating by Credit Suisse given on Wednesday, January 20. Atlantic Securities initiated the shares of AMGN in a report on Friday, December 18 with “Overweight” rating. The firm has “Overweight” rating by Piper Jaffray given on Saturday, August 29. Wells Fargo initiated Amgen, Inc. (NASDAQ:AMGN) on Friday, December 4 with “Market Perform” rating. UBS maintained Amgen, Inc. (NASDAQ:AMGN) on Thursday, October 29 with “Buy” rating. The firm has “Market Perform” rating given on Tuesday, September 1 by Raymond James. Morgan Stanley upgraded the shares of AMGN in a report on Tuesday, December 15 to “Overweight” rating.
According to Zacks Investment Research, “Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.”
Insitutional Activity: The institutional sentiment increased to 1.28 in Q2 2016. Its up 0.21, from 1.07 in 2016Q1. The ratio is positive, as 56 funds sold all Amgen, Inc. shares owned while 422 reduced positions. 77 funds bought stakes while 533 increased positions. They now own 577.82 million shares or 7.76% less from 626.39 million shares in 2016Q1.
Nuveen Asset Mngmt Llc accumulated 447,096 shares or 0.42% of the stock. Baker Avenue Asset Mngmt Lp owns 48,585 shares or 1.11% of their US portfolio. Moreover, Violich Capital Management has 1.46% invested in Amgen, Inc. (NASDAQ:AMGN) for 30,470 shares. Capwealth Advsr Ltd Com, a Tennessee-based fund reported 975 shares. Contravisory Mngmt has 13 shares for 0% of their US portfolio. Rmb Mngmt Ltd Liability holds 51,593 shares or 0.41% of its portfolio. Goelzer Inv Mngmt owns 1,604 shares or 0.03% of their US portfolio. Wheatland Advisors has 3,250 shares for 0.47% of their US portfolio. Cadence Capital Ltd Com accumulated 0.93% or 80,878 shares. Geneva Ltd accumulated 7,634 shares or 0.02% of the stock. Cullinan Associates, a Kentucky-based fund reported 71,400 shares. Turner Invests L P accumulated 0.01% or 175 shares. Reilly Financial Ltd Liability Corporation holds 0.03% or 1,052 shares in its portfolio. Blackrock Group Incorporated holds 7.26M shares or 0.57% of its portfolio. Tower Bridge Advisors last reported 16,489 shares in the company.
Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 1 insider sale for $523,758 net activity. The insider Such Annette Louise sold 3,000 shares worth $523,758.
Amgen Inc. is a biotechnology company. The company has a market cap of $118.76 billion. The Firm discovers, develops, makes and delivers various human therapeutics. It has a 15.08 P/E ratio. The Company’s business segment is human therapeutics.
AMGN Company Profile
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Profitconfidential.com which released: “Amgen, Inc.: This Is Why AMGN Stock is Going Nuts Today” on November 09, 2016, also Fool.com with their article: “Better Buy: Amgen Inc. vs. Johnson & Johnson” published on November 08, 2016, Fool.com published: “5 Things Amgen Inc.’s Management Wants You to Know” on October 28, 2016. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: 247Wallst.com and their article: “Short Sellers Grow More Selective on Major Biotechs” published on November 10, 2016 as well as Investorplace.com‘s news article titled: “Why McKesson Corporation (MCK), Amgen, Inc. (AMGN) and Electronic Arts Inc …” with publication date: October 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.